Background: The heterogeneity of gastric cancer makes the identification of potential prognostic indicators particularly important. The Ki67 and BCL2 proteins are known prognostic markers for different types of cancer. Ki67 is associated with cell proliferation, whereas BCL2 has antiproliferative roles. A combined marker based on these opposite functions might provide improved prognostic information in gastric cancer. Method: Ki67 and BCL2 expression was assessed in 276 gastric adenocarcinoma tissue microarrays. A Ki67/BCL2 index based on the relative expression of each protein was divided into low- and high-risk groups using receiver operating characteristic curves. Results: A high Ki67/BCL2 index significantly correlated with advanced stage, recurrence, intestinal type, high histologic grade, and lymphatic and perineural invasion (all p < 0.05). Univariate and multivariate analyses revealed a significant relationship between disease-free or overall survival and the Ki67/BCL2 index in intestinal-type gastric cancer (all p < 0.05). Conclusions: A combined marker using Ki67 and BCL2 could be a useful indicator for predicting survival in patients with intestinal-type gastric cancer.

Keywords:
bcl-2 homologous antagonist/killer protein, Ki67 antigen, Prognosis, Adenocarcinoma, Stomach, Human
1.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
2.
Shah MA, Khanin R, Tang L, et al: Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011;17:2693-2701.
3.
Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.
4.
Park YS, Na YS, Ryu MH, et al: FGFR2 assessment in gastric cancer using quantitative real-time polymerase chain reaction, fluorescent in situ hybridization, and immunohistochemistry. Am J Clin Pathol 2015;143:865-872.
5.
Cheng H, Wang X, Li T, Chen L: Bcl-2 expression and patient survival in gastric cancer: a systematic review of the literature with meta-analysis. Med Oncol 2015;32:389.
6.
Pyo JS, Sohn JH, Kang G, et al: MUC2 expression is correlated with tumor differentiation and inhibits tumor invasion in gastric carcinomas: a systematic review and meta-analysis. J Pathol Transl Med 2015;49:249-256.
7.
Pillai K, Pourgholami MH, Chua TC, Morris DL: Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res 2013;3:411-423.
8.
Ali HR, Dawson SJ, Blows FM, et al: A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012;226:97-107.
9.
Mikhail M, Velazquez E, Shapiro R, et al: PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005;11:5153-5157.
10.
Cameron RI, Maxwell P, Jenkins D, McCluggage WG: Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41:313-321.
11.
Lee HE, Kim MA, Lee BL, Kim WH: Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol 2010;102:201-206.
12.
Greider C, Chattopadhyay A, Parkhurst C, Yang E: BCL-xL and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 2002;21:7765-7775.
13.
Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
14.
Jovanović MP, Jaković L, Bogdanović A, Marković O, Martinović VC, Mihaljević B: Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. Vojnosanit Pregl 2009;66:738-743.
15.
Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220.
16.
Aizawa K, Ueki K, Suzuki S, et al: Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999;14:85-91.
17.
Saleh HA, Jackson H, Khatib G, Banerjee M: Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 1999;5:273-279.
18.
Laudanski J, Chyczewski L, Niklińska WE, et al: Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma 1999;46:25-30.
19.
Tan PH, Bay BH, Yip G, et al: Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005;18:374-381.
20.
de Manzoni G, Verlato G, Tomezzoli A, et al: Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol 1998;28:534-537.
21.
Goishi H, Tanaka S, Haruma K, et al: Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. Oncol Rep 2000;7:713-718.
22.
Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegård JN, Stenling R: Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 1999;79:577-581.
23.
Strasser A, Huang DC, Vaux DL: The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997;1333:F151-F178.
24.
McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349:254-256.
25.
Zinkel S, Gross A, Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006;13:1351-1359.
26.
Gao CF, Xie Q, Su YL, et al: Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 2005;102:10528-10533.
27.
Lei Z, Tan IB, Das K, et al: Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013;145:554-565.
28.
Turner ES, Turner JR: Expanding the Lauren classification: a new gastric cancer subtype? Gastroenterology 2013;145:505-508.
29.
Gryko M, Pryczynicz A, Zareba K, Kedra B, Kemona A, Guzińska-Ustymowicz K: The expression of Bcl-2 and BID in gastric cancer cells. J Immunol Res 2014;2014:953203.
30.
Kopp R, Diebold J, Dreier I, et al: Prognostic relevance of p53 and bcl-2 immunoreactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections? Surg Endosc 2005;19:1507-1512.
31.
Müller W, Schneiders A, Meier S, Hommel G, Gabbert HE: Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759-765.
32.
Lazăr D, Tăban S, Sporea I, et al: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 2010;51:655-661.
33.
Sueta A, Yamamoto Y, Hayashi M, et al: Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? Surgery 2014;155:927-935.
34.
Li N, Deng W, Ma J, et al: Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol 2015;32:433.
35.
Zhou Y, Li Y, Zheng J, Liu K, Zhang H: Detecting of gastric cancer by Bcl-2 and Ki67. Int J Clin Exp Pathol 2015;8:7287-7290.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.